MedPath

Multicenter Database of Patients With Germ Cell Tumor

Completed
Conditions
Neoplasms, Germ Cell and Embryonal
Registration Number
NCT02863003
Lead Sponsor
Latin American Cooperative Oncology Group
Brief Summary

Retrospective and prospective cohort of patients with germ cell tumor in treatment.

Detailed Description

The primary objective of this study is to create a multicenter database in order to characterize epidemiologically and clinicopathologically patients with germ cell tumor and evaluate the prognosis and clinical outcomes during cancer treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
1315
Inclusion Criteria
  • Male patients with diagnosis of testicular, retroperitoneum or mediastinal primary tumor.
  • Histological confirmation of germ cell tumor or clinical condition based on the elevation of tumor markers (AFP, HCG e/ou DHL) associated to testicular mass or/and retroperitoneal lymphnode enlargement or/and mediastinal mass.
  • Medical records of the disease and treatment
Exclusion Criteria
  • Female patients diagnosed with ovary germ cell tumor
  • Male patients diagnosed with germ cell tumor in other locations.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Brazilian multicenter database in order to collect and analyze data from diagnosis and treatment of patients with germ cell tumorFrom 2000 to 2025
Secondary Outcome Measures
NameTimeMethod
Disease free survival of patients diagnosed with germ cell tumor stage 1.From 2000 to 2025
Overall survival of patients diagnosed with germ cell tumor stage 1.From 2000 to 2025
Description of demographic characteristics of testicular germ cell tumor patients in BrazilFrom 2000 to 2025
The clinical and pathological characteristics of testicular germ cell tumor patients in Brazil.From 2000 to 2025
Treatment according to staging and relapse of patients diagnosed with testicular germ cell tumor in BrazilFrom 2000 to 2025
Disease free survival of patients diagnosed with germ cell tumor stages 2 and 3.From 2000 to 2025
Overall survival of patients diagnosed with germ cell tumor stages 2 and 3.From 2000 to 2025
International prognostic factors in patients with advanced germ cell tumor (stages 2 and 3) stablished by the International Germ Cell Cancer Collaborative Group in brazilian patients.From 2000 to 2025
Treatment outcome in different populations: in patients with brain metastasis, patients with germinative tumor extragonodal, surgery outcome in patients with nonseminomous tumor and ressection of residual lesion after chemotherapyFrom 2000 to 2025
Disease free survival of patients diagnosed with disease relapse after first line chemotherapyFrom 2000 to 2025
Overall survival of patients diagnosed with disease relapse after first line chemotherapyFrom 2000 to 2025
Prognostic model after first line treatment failure with cisplatin, stablished by the International Prognostic Factors Study Group in brazilian patients.From 2000 to 2025

Trial Locations

Locations (4)

Hospital São José

🇧🇷

São Paulo, Brazil

ICESP

🇧🇷

São Paulo, Brazil

Hospital Israelita Albert Einstein

🇧🇷

São Paulo, Brazil

CPO - Pucrs

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

© Copyright 2025. All Rights Reserved by MedPath